Compare
Nano-X Imaging Ltd. vs Escalon Medical Corp vs Hyperfine, Inc. vs Biotricity Inc.
| Latest fiscal year | Nano-X Imaging Ltd. NNOX | Escalon Medical Corp ESMC | Hyperfine, Inc. HYPR | Biotricity Inc. BTCY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2026-03-31 |
| Revenue | $13.02M | $12.74M | $13.56M | $16.00M |
| Revenue growth (YoY) | +15.4% | +5.7% | +5.2% | +16.0% |
| Gross margin | -98.2% | 43.7% (computed) | 49.8% | 80.9% |
| Operating margin | -600.8% | 0.4% | -273.4% | 10.6% |
| Net margin | -576.1% | 31.5% | -262.3% | -15.0% |
| Net income | -$75.02M | $4.01M | -$35.57M | -$2.40M |
| EPS (Diluted) | -$1.16 | $0.27 | -$0.43 | -$0.12 |
| Operating cash flow | -$40.79M | -$402.6K | -$27.95M | -$719.0K |
| Free cash flow | -$45.00M | -$407.0K | -$29.13M | n/a |
| Cash & equivalents | $49.15M | $3.07M | $35.09M | $149.8K |
| Total assets | $162.16M | $9.13M | $55.26M | $6.45M |
| Total liabilities | $22.43M | $3.20M | $14.26M | $39.41M |
| Shareholders' equity | $139.73M | $5.93M | $41.01M | -$34.68M |
| Return on year-end equity | -53.7% | 67.7% | -86.8% | n/a |
| Shares outstanding | n/a | 7.42M | n/a | 28.60M |
Revenue, most recent five fiscal years
| Fiscal year | Nano-X Imaging Ltd. | Escalon Medical Corp | Hyperfine, Inc. | Biotricity Inc. |
|---|---|---|---|---|
| Latest | $13.02M Ended 2025-12-31 | $12.74M Ended 2026-06-30 | $13.56M Ended 2025-12-31 | $16.00M Ended 2026-03-31 |
| 1 year earlier | $11.28M Ended 2024-12-31 | $12.05M Ended 2025-06-30 | $12.89M Ended 2024-12-31 | $13.79M Ended 2025-03-31 |
| 2 years earlier | $9.90M Ended 2023-12-31 | $11.98M Ended 2024-06-30 | $11.03M Ended 2023-12-31 | $12.06M Ended 2024-03-31 |
| 3 years earlier | $8.58M Ended 2022-12-31 | $12.18M Ended 2023-06-30 | $6.81M Ended 2022-12-31 | $9.64M Ended 2023-03-31 |
| 4 years earlier | $1.30M Ended 2021-12-31 | $10.70M Ended 2022-06-30 | $1.50M Ended 2021-12-31 | $7.65M Ended 2022-03-31 |